PRO-DEX, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
PRO-DEX, INC. (PDEX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $7.77 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-03.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-09-03
- PRO-DEX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-09-30 was $95.00K, a 78.89% decline year-over-year.
- PRO-DEX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-09-30 was $450.00K.
- PRO-DEX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-09-30 was -$1.03M, a 152.95% decline year-over-year.
- PRO-DEX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-09-30 was $1.95M, a 33.86% increase year-over-year.
- PRO-DEX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2026 was $7.77M.
- PRO-DEX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$2.21M.
- PRO-DEX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$305.00K, a 114.61% decline from fiscal 2023.
- PRO-DEX, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $2.09M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.77M 10-K · filed 2026-09-03 | |||
| 2026-03-31 | $9.57M 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | $7.53M 10-Q · filed 2026-01-29 | |||
| 2025-09-30 | $95.00K 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | -$2.21M 10-K · filed 2026-09-03 | |||
| 2025-03-31 | $1.84M 10-Q · filed 2026-04-30 | |||
| 2024-12-31 | -$2.56M 10-Q · filed 2026-01-29 | |||
| 2024-09-30 | $450.00K 10-Q · filed 2025-10-30 | |||
| 2024-06-30 | -$305.00K 10-K · filed 2025-09-04 | |||
| 2024-03-31 | $283.00K 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | -$1.65M 10-Q · filed 2025-01-30 | |||
| 2023-09-30 | -$1.03M 10-Q · filed 2024-10-31 | |||
| 2023-06-30 | $2.09M 10-K · filed 2024-09-05 | |||
| 2023-03-31 | $1.24M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | -$467.00K 10-Q · filed 2024-02-08 | |||
| 2022-09-30 | $1.95M 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | -$2.87M 10-K · filed 2023-10-13 | |||
| 2022-03-31 | $1.04M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $1.53M 10-Q · filed 2023-02-02 | |||
| 2021-09-30 | $1.46M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | -$2.70M 10-K · filed 2023-10-13 | |||
| 2021-03-31 | -$2.55M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$898.00K 10-Q · filed 2022-02-03 | |||
| 2020-09-30 | -$1.22M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$1.32M 10-K · filed 2021-09-09 | |||
| 2020-03-31 | -$3.36M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$1.57M 10-Q · filed 2021-02-04 | |||
| 2019-09-30 | -$1.24M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $2.55M 10-K · filed 2020-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |